Edith Schallmeiner,
Global Team Director - NPT,
Novartis
Edith Schallmeiner, PhD, is currently Global Team Director for Near Patient Testing at Novartis. Dr Schallmeiner brings experience from both academia and industry in drug and biomarker early development right through to their commercialization. Dr. Schallmeiner received her PhD in molecular medicine from Uppsala University. Building on her experience in Biomarker discovery and method development she developed and implemented Biomarker Strategies at Merck Serono. Later, she joined Roche Professional Diagnostics to support the development and commercialization of novel companion diagnostics in Alzheimer and Oncology before joining Novartis in her current role.
|
|
Point of Care Diagnostics in Personalized MedicineWednesday, 7 October 2015 at 16:30  Add to Calendar ▼2015-10-07 13:59:002015-10-07 14:59:00Europe/LondonSession 2 – Trends in Personalized Medicine and CNS DiagnosticsPersonalized Medicine and its Impact in the Clinic in Hanover, GermanyHanover, GermanySELECTBIOenquiries@selectbiosciences.comPoint of care diagnostics cover a comparably small portion of existing markers, driven by the historic lack of available technologies with acceptable performance and barriers in access to POC devices. Point of care diagnostics can bring quick and reliable results not only for highly urgent tests but also for improved patient management in a decentralized care settings for a variety of complementary diagnostics.
|
